Aprokam

Cefuroxime

Method of action: Antibacterial Broad Spectrum (Bactericidal), Bactericidal, Bactericidal Broad Spectrum

Treatment option: Abscess, Bacterial Pneumonia, Bronchitis, Bronchiectasis, Gonorrhea, Cataract, Meningitis, Peritonitis, Pneumonia, Surgery

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Aprokam

Aprokam is a sterile medicinal preparation designed to deliver the active ingredient Cefuroxime sodium for specialized bacterial prophylaxis. The drug is fundamentally a single active ingredient product belonging to the broader class of antibiotics, whose primary general purpose is the prevention or elimination of susceptible bacteria in specific clinical contexts.

Quick Facts

Property	Description
Active ingredient	Cefuroxime sodium
Form	Powder for solution for injection
Pharmacological class	Second-generation cephalosporin, Beta-lactam antibiotic
General purpose	Bacterial prophylaxis
Origin	Synthetic

What Type of Medicine is Aprokam?

Aprokam is a medicinal entity whose core component, Cefuroxime sodium, is a second-generation cephalosporin. This substance is synthetic, having been chemically derived to enhance its stability and antibacterial spectrum compared to older compounds in the cephalosporin family, which are themselves members of the larger beta-lactam antibiotic group. This class of antibiotics represents a critical tool in preventative medicine.

Understanding Aprokam’s Composition and Form

The product is supplied as a sterile, white to off-white powder for solution for injection containing only Cefuroxime sodium. This specific dosage form is engineered exclusively for intracameral administration, meaning it is administered directly into a particular localized area by a medical professional. This focus on localized delivery represents a key differentiating factor of this formulation compared to systemic Cefuroxime. The single-ingredient, highly purified nature of the Cefuroxime sodium powder ensures that the medicine can be accurately reconstituted with a sterile base, such as saline solution, immediately prior to its intended localized use.

What is the General Purpose of Aprokam?

The general purpose of Aprokam is to provide reliable, high-concentration bactericidal (bacteria-killing) action for patient protection. Its mechanism, characteristic of the cephalosporin class, involves disrupting the synthesis of the bacterial cell wall, which is an essential structure for microbial survival. This rapid and permanent method of action allows the medicine to fulfill its primary role in prophylaxis to minimize the risk of bacterial presence during and immediately following critical medical procedures.

Regulatory References

What side effects are possible with Aprokam?

Possible side effects and safety information

The safety profile of Aprokam (Cefuroxime sodium for intracameral injection) is based on official regulatory documentation and is classified by the body systems affected and the frequency of occurrence.

Documented Adverse Reactions

The most commonly classified effects fall into the following System Organ Classes (SOC) as listed in the Summary of Product Characteristics (SmPC):

System Organ Class	Adverse Reaction	Frequency Classification
Immune system disorders	Anaphylactic reaction	Very Rare (<1/10,000)
Eye disorders	Macular oedema	Not Known

Anaphylactic reaction is considered a serious adverse reaction, representing a severe systemic allergic response. Macular oedema is a significant local effect associated with the eye that can impact vision. No adverse reactions are classified as Common or Uncommon for this specific localized formulation.

Safety Restrictions and Considerations

The medicine is contraindicated in individuals with known hypersensitivity (allergy) to cefuroxime or any cephalosporin type antibiotics. Regulatory documents also advise caution for patients with a known allergy to penicillins or other beta-lactam antibiotics due to the potential for cross-reactivity.

Safety notes for specific patient groups include the official statement that the optimal dose and safety have not been established in the paediatric population. Use during pregnancy and breast-feeding is generally considered acceptable due to the expected negligible systemic exposure following the localized administration. The risk of Corneal endothelial toxicity is also noted in regulatory texts as a specific potential risk if the product is administered at an unauthorized concentration or incorrectly diluted.

Overdose and Emergency Response

Overdose and when to seek help

Overdose of Aprokam, which contains Cefuroxime sodium, may present with specific manifestations documented in regulatory labeling. Following errors involving incorrectly high doses of the active ingredient administered locally, signs of ocular toxicity have been officially reported, including corneal oedema and loss of corneal endothelial cells. Such high-dose exposure carries the risk of severe outcomes, including permanent and severe vision loss.

In cases of severe systemic overdose, the regulatory documentation describes potential neurological sequelae such as encephalopathy and convulsions, which may escalate to coma. This medicine has no specific antidote, and management is limited to supportive and symptomatic care. To reduce circulating serum levels of Cefuroxime in systemic overdose, procedures like haemodialysis and peritoneal dialysis may be employed.

Immediate medical attention must be sought when any severe neurological symptoms are observed or if severe ocular toxicity is suspected. Regulatory information also notes that patients with impaired renal function are specifically at risk for systemic overdose symptoms if the dosage is not properly reduced, as the medicine is excreted by the kidneys. The primary regulatory action is the explicit injunction to not exceed the single recommended dose for injection.

Therapeutic Uses of Aprokam

Easing Potential Post-Operative Symptomatic Discomfort

This medication is applied across clinical settings to help maintain acute stability following a common surgical procedure. Aprokam is applied for preventative use for reducing the risk of infection after cataract surgery. It is relevant to address the potential for sudden, distressing symptoms, and supports the patient by helping to ease the overall post-surgical burden.

Supporting Management of Acute Symptom Potential

This medicine is commonly used across conditions where an acute event could involve heightened symptoms and increased physiological stress. This includes situations requiring symptomatic support following procedures involving the eye. Its use may assist with reducing the potential for systemic or localized discomfort in an acute context, thereby helping to manage the potential for symptoms that interfere with daily comfort. This supports general well-being during symptomatic phases. Its application is relevant when short-term symptomatic assistance is needed following the procedure.

Quick Fact: Relevant for Symptoms Related to Acute Infection Potential

Addressing Potential Functional Strain

This agent is generally used to help with symptoms that could create noticeable functional strain in the immediate post-operative phase, specifically those associated with microbial activity. Its application may contribute to improved comfort during symptomatic periods and assists with maintaining functional stability by managing the key risk of symptoms that might otherwise cluster into a significant discomfort. It is applied in clinical settings marked by temporary physiological imbalance.

Regulatory References

Haute Autorité de Santé (HAS) assessment

Eligibility and Restrictions for Use

Who Can and Cannot Use Aprokam?

The official eligibility for Aprokam (Cefuroxime sodium) is defined by regulatory documents based on patient characteristics and pre-existing conditions.

Contraindicated Populations

Use of Aprokam is absolutely contraindicated in patients with a known hypersensitivity to the active substance cefuroxime or to any antibiotic belonging to the wider cephalosporin group. Special care is indicated for individuals with a history of allergic reaction to penicillins or other beta-lactam antibiotics, as cross-reactions may occur.

Age- and Condition-Based Eligibility

The medicine is permitted for use in the adult and older adult populations, with no dose adjustment required for the elderly or for patients with renal or hepatic impairment. This is based on the negligible systemic exposure expected from its localized administration. Use is explicitly not established in the paediatric population, as official data on optimal dose and safety are not available.

Conditional Use and Restrictions

Aprokam can be used during both pregnancy and breastfeeding based on its low systemic absorption. However, use requires careful consideration for specific special patient groups, including those with severe risk of infection, complicated cataracts, or a history of infection with resistant strains (such as MRSA), where an alternative prophylactic antibiotic may be advised.

What should I know about interactions with other medicines?

The official regulatory documents define the interaction profile of Aprokam (Cefuroxime sodium) based on interactions established for the systemically administered active substance, while acknowledging the negligible systemic exposure from its specific localized, single-dose use.

Pharmacokinetic and Pharmacodynamic Interactions

The profile highlights a pharmacokinetic interaction involving the medicine Probenecid. Co-administration with Probenecid formally results in the inhibition of Cefuroxime's renal tubular clearance, which leads to an officially documented increase in Cefuroxime plasma concentrations and a prolonged elimination half-life. This interaction is noted as clinically significant.

A separate pharmacodynamic interaction risk is noted with other nephrotoxic drugs, such as aminoglycosides or potent diuretics. Regulatory labels state that combining Cefuroxime with these substance categories carries an additive risk of nephrotoxicity.

Restrictions and Diagnostic Interference

The product’s intracameral route of administration results in no documented interactions with general metabolic enzymes, food, or alcohol, as stated in the regulatory documentation. However, the official profile specifies interference with diagnostic procedures: Cefuroxime may cause a false-positive result for the Coombs’ test and interference with non-enzymatic copper reduction tests for glucose. No specific drug combination is listed as a formal contraindication based on interaction risk alone.

Mechanism of Action

Irreversible Blockade of Bacterial Cell Wall Synthesis

Aprokam’s active ingredient, Cefuroxime sodium, exerts its action by covalently and irreversibly inhibiting a specific family of bacterial enzymes called Penicillin-Binding Proteins (PBPs) . These PBPs are critical for the final peptidoglycan cross-linking step, which constructs the rigid structural layer of the bacterial cell wall. This enzyme blockade halts bacterial growth and leads to the subsequent loss of structural integrity.

Cascade Leading to Bactericidal Action and Microbial Lysis

The structural failure caused by PBP inhibition triggers a rapid mechanistic cascade within the bacteria, activating its own autolytic enzymes. The combined structural weakness and internal degradation cause the exposed bacterial cell to rupture due to osmotic pressure (lysis), resulting in a rapid bactericidal effect due to the mechanism of cell lysis. This rapid destruction of the bacterial cell is the core physiological consequence of the drug's mechanism.

Mechanism Limitations: Enzymatic Bypass

The drug's core mechanism is functionally constrained when bacteria produce beta-lactamase enzymes that chemically neutralize the drug before it can bind to the PBPs, or when the PBPs themselves undergo mutations that reduce binding affinity. In these scenarios, the cell wall synthesis pathway is no longer inhibited, allowing the resistant organisms to maintain cell wall integrity and viability.

Dosage and Administration Information

Aprokam is an antibacterial medicine strictly indicated for single-use administration by an ophthalmic surgeon at the conclusion of cataract surgery. This product is formulated as a powder for a solution and must be administered only via intraocular injection into the anterior chamber of the eye (intracameral use) under sterile conditions.

Official Dosing and Preparation

The recommended dose for adults is 0.1 ml of the reconstituted solution, which delivers 1 mg of cefuroxime. This dosage must not be exceeded. The use of one vial is restricted to a single-use only. Aprokam must be reconstituted before use with 5 ml of sodium chloride 9 mg/ml (0.9%) solution for injection under aseptic technique. After reconstitution, the solution must be visually inspected and should be a clear, colorless to yellowish solution free from visible particles. The reconstituted solution must be used immediately and cannot be stored or reused.

Administration Detail	Guideline
Route of Administration	Intraocular injection into the anterior chamber (Intracameral)
Standard Adult Dose	1 mg of cefuroxime (delivered in 0.1 ml of reconstituted solution)
Frequency	Single-dose, one-time injection at the end of surgery

For administration, the 0.1 ml dose must be slowly injected into the anterior chamber. No dose adjustment is required for elderly patients or those with hepatic and renal impairment due to the negligible systemic exposure. The optimal dose and safety have not been established in the paediatric population.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Aprokam

This section summarizes the official clinical evaluation landscape for Cefuroxime sodium (Aprokam), focusing on the types of studies that exist and the specific outcomes they were designed to measure, according to regulatory and scientific sources.

Evidence for Prophylaxis After Cataract Surgery

The evidence landscape for the active ingredient's specialized use is built upon a large, multinational Randomized Controlled Trial (RCT), alongside Systematic Reviews and observational studies. These trials focused on adults undergoing routine cataract surgery with lens implantation.

What Researchers Studied: The key research was studied for patterns in a condition called post-operative endophthalmitis (POE), which is a severe infection that may occur after the procedure. The primary outcome measured in the pivotal study was observed in the rate or incidence of confirmed or suspected POE in the observed population.

What the Studies Reported: The primary RCT reported measurements of the rate of the primary outcome (POE), noting a pattern where this rate was lower in the population receiving the active ingredient compared to the comparator population. Scientific reviews that pooled data from multiple studies contribute to the broader evidence landscape regarding specific medical procedures.

Types of Clinical Research and Outcomes Studied

The evidence for the clinical evaluation is broadly assigned a coarse Evidence Level of High based on the existence of a definitive, large-scale clinical trial.

Study Designs: The regulatory foundation relies heavily on a large RCT where the active ingredient was evaluated in a comparison against a non-active solution. This high-level evidence is supplemented by numerous large observational studies that monitor outcomes across thousands of patients in real-world clinical use.

Outcomes Tracked: The main research examined outcomes related to the incidence of acute post-operative endophthalmitis. Secondary outcomes studies monitored local effects, such as tracking changes in the layer of cells on the inner surface of the cornea and monitoring intraocular pressure immediately after the procedure.

Understanding Research Limitations and Uncertainties

Limited Subgroup Data: Regulatory authorities have noted that data for certain groups remain insufficient. For instance, the full evidence base for the pediatric population (children undergoing congenital cataract surgery) is not fully established, meaning the current research provides limited information for this group. The results from the main evidence base apply only to the populations studied.

Long-Term Follow-up: The outcomes related to the studied condition were typically observed in studies for a short-term duration. While some observational data extends tracking to several months, long-term effects are not fully established.

Frequently Asked Questions (FAQ)

Common questions about Aprokam (FAQ)

Q: Is Aprokam the same type of medicine as other drugs used for the same procedure?

Aprokam is described in official documents as the first proprietary medicine containing Cefuroxime sodium, which is a type of cephalosporin antibiotic, specifically authorized for use during cataract surgery. While official records acknowledge that unlicensed preparations of Cefuroxime or other antibiotics may have been used for the same purpose, Aprokam is the first formulation licensed for this specific indication.

Q: Are there different strengths or concentrations of Aprokam?

Aprokam is supplied in a single format: a powder containing 50 mg of Cefuroxime. The medicine is reconstituted to a specific concentration by a healthcare professional immediately before it is used, which is then used to draw up the dose intended for administration.

Q: Can patients who are pregnant or breastfeeding receive Aprokam?

Official information indicates that the use of Aprokam during both pregnancy and breastfeeding is generally considered acceptable. This is based on the expectation that very little of the medicine enters the body's main circulation (negligible systemic exposure) due to its localized administration directly into the eye.

Q: Is Aprokam known to cause temporary blurry vision?

The official product information does not list temporary blurred vision as a common or uncommon side effect for the licensed medication. However, the term 'vision blurred' has been noted in safety literature related to non-approved preparations of Cefuroxime when used for the same purpose.

Q: Are there foods or drinks that should be avoided when receiving Aprokam?

According to official regulatory documentation, Aprokam's specialized route of administration (injection into the eye) results in no documented interactions with general metabolic enzymes, food, or alcohol. The regulatory documents do not specify the need for dietary restrictions related to the medicine itself.

Q: How quickly does Aprokam start working?

Pharmacokinetic analysis shows that the active substance in Aprokam reaches high levels in the anterior chamber of the eye (the area where it is injected) within 30 seconds of administration. These high concentrations in the anterior chamber are maintained to support the drug’s intended use.

Q: How long does the effect of Aprokam usually last?

Official pharmacokinetic data indicates that the concentration of the active substance in the eye's anterior chamber remains above the level needed to inhibit target bacteria for approximately 4 to 5 hours following the surgical procedure.

Q: Can Aprokam cause long-term vision problems?

The official evidence base for this specific use of Aprokam primarily relies on studies with short-term follow-up. While some observational data extends tracking to several months, the evidence base for long-term effects is limited. Macular oedema (swelling in the eye) is listed as a potential, very rare adverse reaction.

Q: Is Aprokam a preservative-free formulation?

Yes. Official information states that the Aprokam powder contains only the active substance, Cefuroxime sodium, and is formulated without excipients (non-active ingredients). The medicine is reconstituted with a sterile solution immediately before use.

Q: Does Aprokam contain sulfa or latex?

The Aprokam powder contains only the active ingredient, Cefuroxime sodium, and no excipients; it is not a sulfa-containing drug. Additionally, the vial stopper is made of bromobutyl and is not described as containing latex.

Q: What should I do if I notice unusual eye redness after the procedure involving Aprokam?

Clinical studies have noted the temporary presence of conjunctival hyperemia (eye redness) in the first week following the surgical procedure. Official guidelines provide information for patients to report any adverse events or concerns to their treating doctor or pharmacist.

Q: Why is my doctor asking me about my allergies before using Aprokam?

Your doctor asks about allergies because official safety documents state that Aprokam is contraindicated (should not be used) in patients with a known allergy to Cefuroxime or any antibiotic in the wider cephalosporin group. Caution is also advised regarding allergies to penicillins due to the potential for allergic cross-reactivity between the drug types.

Q: What does the term 'single-use vial' mean for Aprokam?

The term 'single-use vial' means that one vial is intended for use for one patient during a single procedure only. Official documentation states that any unused portion of the medicine remaining in the vial or the syringe after administration must be discarded immediately and cannot be saved or reused.

How should Aprokam be stored and disposed of?

How to Store and Dispose of Aprokam

Storage and disposal of Aprokam (cefuroxime) powder for injection must strictly follow the official regulatory requirements to maintain product stability and ensure safe handling.

Official Storage Requirements

Temperature: The unopened vial must be stored at a temperature below 25°C.
Protection: The vial must be kept in the original outer carton to protect the product from light.
Child Safety: This medicine must be stored out of the sight and reach of children.

Stability and Use

The vial is for single use only.
The reconstituted solution must be used immediately after preparation; no subsequent storage of the solution is permitted.
Do not use the medicine after the expiry date printed on the carton and vial label.

Disposal Instructions

Any unused medicinal product, expired medicine, or associated waste material must be disposed of in accordance with local requirements. Medicines must not be thrown away via wastewater or household waste. Used needles and related sharps must be properly discarded in a designated sharps container.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.